MBX Biosciences Inc [MBX] stock is trading at $12.25, down -0.89%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MBX shares have gain 20.45% over the last week, with a monthly amount glided 41.78%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MBX Biosciences Inc [NASDAQ: MBX] stock has seen the most recent analyst activity on April 10, 2025, when Citizens JMP initiated its Mkt Outperform rating and assigned the stock a price target of $38. Previously, Stifel started tracking the stock with Buy rating on October 08, 2024, and set its price target to $40. On October 08, 2024, JP Morgan initiated with a Overweight rating and assigned a price target of $30 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $35 on October 08, 2024. Guggenheim initiated its recommendation with a Buy and recommended $44 as its price target on October 08, 2024.
MBX Biosciences Inc [MBX] stock has fluctuated between $4.81 and $27.50 over the past year. Currently, Wall Street analysts expect the stock to reach $44 within the next 12 months. MBX Biosciences Inc [NASDAQ: MBX] shares were valued at $12.25 at the most recent close of the market. An investor can expect a potential return of 259.18% based on the average MBX price forecast.
Analyzing the MBX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.44 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, MBX Biosciences Inc’s Current Ratio is 23.31. As well, the Quick Ratio is 23.31, while the Cash Ratio is 2.85.
Transactions by insiders
Recent insider trading involved Pescovitz Ora H., Director, that happened on Apr 08 ’25 when 7693.0 shares were purchased. Director, GORDON CARL L completed a deal on Feb 18 ’25 to buy 0.14 million shares. Meanwhile, Director GORDON CARL L bought 47502.0 shares on Feb 14 ’25.
